Follow The Filings

RMD ResMed

Health Care, filed as RESMED INC (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.0%
  • $80K

Who owns this now

Largest portfolio weights among holders, up to 0.0% (Kentucky Trust Co., Kentucky Trust). Not free-float ownership.

  1. Kentucky Trust Co. 0.04%

Who owns RMD

Sorted by value, long equity only, as of 2026 Q3.

History
Kentucky Trust Co., Kentucky Trust 0.04% Hold 360 $80K History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by RMD's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RMD insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $22.4M sold by 5 insiders under 10b5-1 plans
  1. Michael J Rider Global General Counsel
    Planned sale
    $102K 400 shares at $255.00 3.1% of stake
    Traded Oct 23 Filed Oct 26
    ↗
  2. Michael J. Farrell CEO
    Planned sale
    $1.1M 4,991 shares at $226.33 1% of stake
    Traded Oct 7 Filed Oct 8
    ↗
  3. Michael J. Farrell CEO
    Planned sale
    $1.1M 4,991 shares at $222.44 1.1% of stake
    Traded Sep 8 Filed Sep 10
    ↗
  4. Peter C Farrell Director
    Planned sale
    $228K 970 shares at $234.73 1.8% of stake
    Traded Sep 2 Filed Sep 4
    ↗
  5. Michael J. Farrell CEO
    Planned sale
    $1M 4,991 shares at $205.69 1.1% of stake
    Traded Aug 7 Filed Aug 11
    ↗
  6. Peter C Farrell Director
    Planned sale
    $1.8M 8,000 shares at $225.00 13% of stake
    Traded Aug 5 Filed Aug 6
    ↗
  7. Michael J. Farrell CEO
    Planned sale
    $1.1M 4,991 shares at $218.55 1.1% of stake
    Traded Jul 7 Filed Jul 9
    ↗
  8. Michael J. Farrell CEO
    Planned sale
    $968K 4,991 shares at $193.96 1.1% of stake
    Traded Jun 8 Filed Jun 9
    ↗
  9. Michael J. Farrell CEO
    Planned sale
    $1M 4,991 shares at $207.82 1.1% of stake
    Traded May 7 Filed May 11
    ↗
  10. Michael J. Farrell CEO
    Planned sale
    $1.1M 4,991 shares at $225.50 1.1% of stake
    Traded Apr 7 Filed Apr 9
    ↗
  11. Brett Sandercock CFO
    Planned sale
    $224K 1,000 shares at $224.31 1.2% of stake
    Traded Apr 1 Filed Apr 3
    ↗
  12. Peter C Farrell Director
    Planned sale
    $450K 2,000 shares at $225.00 3.2% of stake
    Traded Apr 1 Filed Apr 2
    ↗
  13. Michael J. Farrell CEO
    Planned sale
    $1.3M 4,991 shares at $251.03 1.1% of stake
    Traded Mar 9 Filed Mar 11
    ↗
  14. Peter C Farrell Director
    Planned sale
    $520K 2,000 shares at $260.22 3.1% of stake
    Traded Mar 4 Filed Mar 5
    ↗
  15. Brett Sandercock CFO
    Planned sale
    $254K 1,000 shares at $254.30 1.2% of stake
    Traded Mar 2 Filed Mar 3
    ↗

Also filed in the last 12 months, not counted as buying or selling: 17 stock grants, 15 option exercises, and 13 share withholdings for taxes.

Congress

4 members of Congress traded RMD in the last three years: 1 buy and 7 sales. 5 members listed it in 2025 annual reports.

All Congress trades
  1. Alan Armstrong R-OK Buy $1K–$15K Mar 27 filed Jul 21
  2. Kelly Morrison D-MN-3 Sell $1K–$15K Jun 4, 2025 filed Jun 18, 2025
  3. Kelly Morrison D-MN-3 Sell $1K–$15K Jun 4, 2025 filed Jun 18, 2025
  4. Kelly Morrison D-MN-3 Sell $1K–$15K Jun 4, 2025 filed Jun 18, 2025
  5. Kelly Morrison D-MN-3 Sell $1K–$15K Jun 4, 2025 filed Jun 18, 2025
  6. Kelly Morrison D-MN-3 Sell $1K–$15K Apr 28, 2025 filed May 13, 2025

SEC filings

Recent issuer filings from EDGAR, 17 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 8.01 Filing Doc
8-K 4.01,5.02,7.01,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated about 3 hours ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025 FY2026
Revenue $4.22B $4.69B $5.15B $5.65B
Gross profit $2.36B $2.66B $3.05B $3.45B
Gross margin * 55.8% 56.7% 59.4% 61.1%
Net income $0.898B $1.02B $1.4B $1.52B
Net margin * 21.3% 21.8% 27.2% 26.9%

Balance sheet

Metric FY2023 FY2024 FY2025 FY2026
Total current assets $2.37B $2.36B $3.51B $4.32B
Total non-current assets $4.38B $4.51B $4.67B $4.64B
Total assets $6.75B $6.87B $8.17B $8.97B
Total current liabilities $0.759B $0.911B $1.02B $1.4B
Total non-current liabilities $1.86B $1.1B $1.19B $0.985B
Total equity $4.13B $4.86B $5.97B $6.59B

Cash flow

Metric FY2023 FY2024 FY2025 FY2026
Cash from operations $0.693B $1.4B $1.75B $1.81B
Cash from investing -$1.16B -$0.27B -$0.2B -$0.545B
Cash from financing $0.423B -$1.12B -$0.606B -$1.01B
Net change in cash -$45.82M $10.47M $971.09M $259.78M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.